Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | F2 | P00734 | 1/20 | 0.72 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160965 | 1.00 | F10 (0.76) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18897606 | 1.00 | F10 (0.76) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1160964 | 0.90 | MAOB (0.62) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL78345 | 0.86 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19230362 | 0.86 | F10 (0.87) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL806189 | 0.86 | F10 (0.87) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL78508 | 0.86 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15326026 | 0.85 | F10 (0.81) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL806187 | 0.85 | F10 (0.74) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18897718 | 0.84 | F10 (0.74) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105738489-B | method for determining rivaroxaban and impurities thereof by adopting liquid chromatography | 重庆医药工业研究院有限责任公司 | 2020-01-31 | — | — | CN | claimed |
| EP-2459555-B1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA D D NOVO MESTO (SI) | 2021-11-03 | — | — | EP | disclosed |
| CN-105738489-B | method for determining rivaroxaban and impurities thereof by adopting liquid chromatography | 重庆医药工业研究院有限责任公司 | 2020-01-31 | — | — | CN | disclosed |
| WO-2013041651-A1 | NOVEL CRYSTALLINE FORMS OF RIVAROXABAN AND PROCESSES FOR THEIR PREPARATION | ENANTIA, S.L. (ES) | 2013-03-28 | — | — | WO | disclosed |
| EP-2521723-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Enantia, S.L. (ES) | 2012-11-14 | — | — | EP | disclosed |
| EP-2459555-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., Novo Mesto (SI) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
| EP-1934208-B1 | NOVEL POLYMORPHOUS FORM OF 5-CHLORO-N-({ (5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDINE-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER SCHERING PHARMA AG (DE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2011012321-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., NOVO MESTO (SI) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012321-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., NOVO MESTO (SI) | 2011-02-03 | — | — | WO | disclosed |
| EP-1934208-A1 | NOVEL POLYMORPHOUS FORM AND THE AMORPHOUS FORM OF 5-CHLORO-N-({ (5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDINE-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039132-A1 | NOVEL POLYMORPHOUS FORM AND THE AMORPHOUS FORM OF 5-CHLORO-N-({ (5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDINE-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |